Headquartered in Palo Alto, CA·Fiscal year ends December·NASDAQ: GH·guardanthealth.com
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based cancer tests, real-world data and AI analytics. Its tests are used across the cancer care continuum:
- **Screening:** the Shield blood test for colorectal cancer screening, now covered for more than 80% of eligible lives commercially.
- **Recurrence monitoring:** Guardant Reveal, including Guardant Reveal Ultra, for early-stage cancer patients.
- **Therapy selection:** Guardant360 CDx liquid biopsy and Guardant360 Tissue (PMA submitted) for patients with advanced cancer.
Guardant360 CDx holds FDA companion diagnostic approvals, including recent approvals in breast cancer for AstraZeneca's camizestrant and Lilly's imlunestrant.
The company reports revenue across four categories:
- Oncology (clinical testing)
- Biopharma & Data (services and data for pharmaceutical partners)
- Screening (Shield)
- Licensing and other Updated
A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of…
Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the…
Thursday's top analyst upgrades and downgrades included DocuSign, Etsy, Guardant Health, International Paper, Johnson Controls, Kosmos Energy, Levi Strauss, Snowflake, Tesla, Topgolf Calloway Brands, WW International and XPO.
Tuesday's top analyst upgrades and downgrades included Broadcom, Caterpillar, CVS Health, Guardant Health, Marvell Technology, Nutrien, Paramount Global, RingCentral, SoFi Technologies, UnitedHealth Group and Workday.
Tuesday's additional analyst upgrades and downgrades included Carvana, Exxon Mobil, Horizon Therapeutics, Norfolk Southern, Principal Financial, Under Armour and Ventas.